TY  - JOUR
AU  - García-Muñoz, Ricardo
AU  - Quero, Cristina
AU  - Pérez-Persona, Ernesto
AU  - Domingo-García, Abel
AU  - Pérez-López, Cristina
AU  - Villaescusa-de-la-Rosa, Teresa
AU  - Martínez-Castro, Ana M
AU  - Arguiñano-Pérez, José M
AU  - Parra-Cuadrado, Juan F
AU  - Panizo, Carlos
PY  - 2019
DO  - 10.1111/bjh.16227
UR  - http://hdl.handle.net/10668/14571
T2  - British journal of haematology
AB  - Rituximab is a standard treatment for non-Hodgkin diffuse large B-cell (DLBCL) and follicular (FL) lymphomas. A subcutaneous formulation was developed to improve the resource use of intravenous rituximab, with comparable efficacy and safety profiles...
LA  - en
KW  - administration-related reactions
KW  - follicular lymphoma
KW  - non-Hodgkin diffuse large B-cell lymphoma
KW  - rituximab
KW  - safety
KW  - Administration, Intravenous
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Disease-Free Survival
KW  - Female
KW  - Humans
KW  - Infusions, Subcutaneous
KW  - Lymphoma, Large B-Cell, Diffuse
KW  - Male
KW  - Middle Aged
KW  - Quality of Life
KW  - Rituximab
KW  - Safety
KW  - Spain
KW  - Survival Rate
TI  - Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study.
TY  - research article
VL  - 188
ER  -